Takeda to invest Y20B in iPS research

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said it will invest Y20 billion ($168 million) over 10 years to develop clinical applications of induced pluripotent stem (iPS) cells under a new research collaboration with the Center for iPS Cell Research Application (CiRA) of Kyoto University.

The Takeda-CiRA Joint Program for iPS Cell Applications (T-CiRA) will sponsor research projects in areas such as heart failure, diabetes, neurological disorders and cancer immunotherapy. ...